Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
Lyell Immunopharma initiated the Phase 3 PiNACLE–H2H trial of ronde-cel in large B-cell lymphoma and reported that GI prophylaxis reduced severe diarrhea rates from 55% to 10% in the Phase 1 LYL273 trial.
Magnesium supplements can interact with antibiotics and bone-loss drugs, reducing their effectiveness. High doses may cause diarrhea, nausea, and low blood pressure. Experts advise talking to a health care provider before use.
Eli Lilly will file its triple-agonist obesity drug retatrutide in early 2027 via a Biologics License Application, seeking stronger market protections. Positive Phase 3 results showed up to 22.6% weight loss, while cardiovascular safety data raised some questions.
FDA approved zenocutuzumab-zbco (Bizengri) for NRG1 fusion-positive cholangiocarcinoma on May 8, 2026. The eNRGy trial showed a 36.8% ORR. It also received priority review, breakthrough, and orphan designations.
The FDA has accepted for review a supplemental application for taletrectinib in advanced ROS1-positive NSCLC, with a PDUFA date of January 4, 2027. Updated TRUST-I and TRUST-2 data showed high response rates, durable responses and no new safety signals.
LIB Therapeutics launched Lerochol in the United States after FDA approval for lowering LDL-C in adults with hypercholesterolemia, including HeFH. The once-monthly PCSK9 inhibitor is available with a $199-per-month cash-pay option.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
Updated phase I data showed zoldonrasib produced a 52% confirmed objective response rate and 93% disease control rate in previously treated KRAS G12D-mutant NSCLC. No grade 4 or higher treatment-related adverse events were observed at the recommended phase II dose.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07758933 |
Safety of Lactobacillus LB Postbiotic in Immunocompromised Paediatric Patients With Diarrhoeal Disease |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07683364 |
Bristol Stool Scale-Based Care Pathway for Enteral Nutrition-Associated Diarrhea in Critically Ill Patients |
NOT_YET_RECRUITING | NA |
| NCT07668765 |
GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity |
NOT_YET_RECRUITING | |
| NCT07610382 |
Balanced Crystalloid vs Normal Saline in Pediatric Acute Gastroenteritis |
RECRUITING | |
| NCT07601503 |
Evaluating In-line Chlorination in Nigeria |
NOT_YET_RECRUITING | NA |
| NCT07569172 |
Improved Child Nutrition and Development Through Social Transfers |
NOT_YET_RECRUITING | NA |
| NCT07545759 |
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) |
RECRUITING | PHASE2 |
| NCT07484412 |
Efficacy and Safety of Encapsulated Bifidobacterium Longum BBH016 in Subjects With Lower Gastrointestinal Symptoms |
ACTIVE_NOT_RECRUITING | NA |
| NCT07436104 |
Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat. |
COMPLETED | PHASE4 |
| NCT07385196 |
Defining Ileorectal Syndrome: a Prospective Observational Study |
RECRUITING |
